John was diagnosed with multiple myeloma more than 16 years ago through a routine blood test revealing elevated proteins. He is cycling as a “small token of my gratitude,” he said, for all that MMRF has done for myeloma patients, researchers and medical providers. Since 2006, he has endured numerous types of treatments, buoyed by incredible medical advancements, dedicated medical providers, family and friends, and spiritual inspiration, he adds. Busch is also riding “for all the folks who can’t participate,” he said. “It is a blessing to be able and fit enough to do something extraordinary like this ride.”
At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.
About Janssen OncologyClick below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.
Learn More
